Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL

JCO Global Oncology 2026 Open access

Read full text
Authors: Julia Esther Colunga Pedraza, Andrés Gómez-De León, Perla R. Colunga Pedraza, Ingrid Gabriela López Reyna, Claudia Gabriela Martínez Martínez, Yahaira Valentina Jiménez Antolinez, José Carlos Jaime‐Pérez, David Gómez Almaguer, Óscar González Llano
DOI: 10.1200/go-25-00469
Cited by: 2
References: 22

Abstract

PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research CAR-T cell therapy research Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
JCO Global Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
12
Issue
2
Pages
e2500469–e2500469
Publication date
1 February 2026
Language
EN